Resveratrol
Özet
Doğal ürün bileşikleri, kanser de dahil olmak üzere iltihap kaynaklı hastalıklara karşı güçlü etkilere sahiptir. Resveratrol, genellikle üzüm, yer fıstığı, meyveler ve tahıllar gibi günlük insan diyetinde bulunan, antioksidan, anti-inflamatuar, kardiyoprotektif ve anti-kanser özelliklerine sahip doğal bir fitokimyasaldır. Kanser oluşumu karmaşık bir süreçtir ve tümörü ilerleten inflamasyon, kanserin ayırt edici özelliklerinden biridir. Resveratrolün meme, serviks, endometrium, kan, böbrek, karaciğer, göz, mesane, tiroid, özefagus, prostat, beyin, akciğer, cilt, mide, kolon, baş ve boyun, kemik ve over dahil olmak üzere farklı insan kanserlerini azaltmadaki rolü gözden geçirilmiştir. Resveratrolün standart kemoterapötiklerle birlikte kullanıldığında kanser hücrelerini bunlara duyarlı hale getirebildiği bildirilmiştir.
Natural product compounds have potent effects against inflammation-driven diseases, including cancer. Resveratrol is a natural phytochemical that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties which is usually found in daily human diet such as grape, peanut, berries and grains. Cancer formation is a complex process and tumor promoting inflamation is one of the hallmarks of cancer. Resveratrol’s role in reducing different human cancers some of which are: breast, blood, liver, brain, lung, skin, gastric, colon, have been reviewed. It has been reported that when resveratrol used with standart chemotherapeutics, it can sensitize cancer cells to them.
Referanslar
Shanmugam, M.K.; Kannaiyan, R.; Sethi, G. Targeting cell signaling and apoptotic pathways by dietary agents: Role in the prevention and treatment of cancer. Nutr. Cancer 2011, 63, 161–173.
Shanmugam, M.K.; Nguyen, A.H.; Kumar, A.P.; Tan, B.K.; Sethi, G. Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer. Cancer Lett. 2012, 320, 158–170.
Shanmugam, M.K.; Lee, J.H.; Chai, E.Z.; Kanchi, M.M.; Kar, S.; Arfuso, F.; Dharmarajan, A.; Kumar, A.P.; Ramar, P.S.; Looi, C.Y.; et al. Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds. Semin. Cancer Biol. 2016, 40–41, 35–47.
Prasannan, R.; Kalesh, K.A.; Shanmugam, M.K.; Nachiyappan, A.; Ramachandran, L.; Nguyen, A.H.; Kumar, A.P.; Lakshmanan, M.; Ahn, K.S.; Sethi, G. Key cell signaling pathways modulated by zerumbone: Role in the prevention and treatment of cancer. Biochem. Pharmacol. 2012, 84, 1268–1276.
A. Wahab, K. Gao, C. Jia, F. Zhang, G. Tian, G. Murtaza, J. Chen, Significance of resveratrol in clinical management of chronic diseases, Molecules 22 (2017),
J.-H. Ko, G. Sethi, J.-Y. Um, M.K. Shanmugam, F. Arfuso, A.P. Kumar, A. Bishayee, K.S. Ahn, The role of resveratrol in cancer therapy, Int. J. Mol. Sci. 18 (2017) 2589,
M. Jang, L. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W. Beecher, H.H. Fong,
N.R. Farnsworth, A.D. Kinghorn, R.G. Mehta, et al., Cancer chemopreventive activity of resveratrol, a natural product derived from grapes, Science (New York, N.Y.) 275 (1997) 218–220,
S.H. Baek, J.-H. Ko, H. Lee, J. Jung, M. Kong, J.-w. Lee, J. Lee, A. Chinnathambi, M. E. Zayed, S.A. Alharbi, et al., Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: role in apoptosis induction and radiosensitization in head and neck tumor cells, Phytomedicine 23 (2016) 566–577.
K.B. Harikumar, A.B. Kunnumakkara, G. Sethi, P. Diagaradjane, P. Anand, M. K. Pandey, J. Gelovani, S. Krishnan, S. Guha, B.B. Aggarwal, Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer, Int. J. Canc. 127 (2010) 257–268
Jang, M., L. Cai, G.O. Udeani, et al. 1997. Cancer chemo- preventive activity of resveratrol, a natural product derived from grapes. Science 275: 218–220.
Kumar, S., E. Eroglu, J.A. Stokes, 3rd, et al. 2017. Resveratrol induces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancer cells. Oncotarget 8: 20895–20908.
Vendrely, V., E. Peuchant, E. Buscail, et al. 2017. Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model. Cancer Lett. 390: 91– 102.
(thickness >3 mm) or regional lymph node metastasis. Eur J Cancer. 2004;40(3):390-402.
Low, I.C., Z.X. Chen & S. Pervaiz. 2010. Bcl-2 modulates resveratrol-induced ROS production by regulating mitochondrial respiration in tumor cells. Antioxid. Redox Signal. 13: 807–819.
Cao, L., X. Chen, X. Xiao, et al. 2016. Resveratrol inhibits hyperglycemia-driven ROS-induced invasion and migration of pancreatic cancer cells via suppression of the ERK and p38 MAPK signaling pathways. Int. J. Oncol. 49: 735–743.
Thiel, G. & O.G. Rossler. 2014. Resveratrol stimulates AP-1- regulated gene transcription. Mol. Nutr. Food Res. 58: 1402– 1413.
Kong,Y.,G.Chen,Z.Xu,etal.2016.Pterostilbeneinduces apoptosis and cell cycle arrest in diffuse large B-cell lym- phoma cells. Sci. Rep. 6: 37417.
Cote, C.D., B.A. Rasmussen, F.A. Duca, et al. 2015. Resvera- trol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat. Med. 21: 498–505.
Farrand, L., S. Byun, J.Y. Kim, et al. 2013. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modula- tion of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission. J. Biol. Chem. 288: 23740–23750.
Li, W., J. Ma, Q. Ma, et al. 2013. Resveratrol inhibits the epithelial–mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-kappaB pathway. Curr. Med. Chem. 20: 4185–4194.
Li, W., L. Cao, X. Chen, et al. 2016. Resveratrol inhibits hypoxia-driven ROS-induced invasive and migratory ability of pancreatic cancer cells via suppression of the Hedgehog signaling pathway. Oncol. Rep. 35: 1718–1726.
Jiang, Z., X. Chen, K. Chen, et al. 2016. YAP inhibition by resveratrol via activation of AMPK enhances the sensitivity of pancreatic cancer cells to gemcitabine. Nutrients 8: 546.
Thiel, G. & O.G. Rossler. 2014. Resveratrol stimulates AP-1- regulated gene transcription. Mol. Nutr. Food Res. 58: 1402– 1413.
Zhu, Y., Y. Sun, W. Guan, et al. 2016. Lycium barbarum polysaccharides enhances SIRT1 expression and decreases MMP-9 and HIF-1expressions in hypoxic pulmonary vas- cular smooth muscle cells. Xi bao yu fen zi mian yi xue za zhi 32: 906–910.
Baek, S.H., J.H. Ko, H. Lee, et al. 2016. Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: role in apoptosis induction and radiosensitization in head and neck tumor cells. Phytomedicine 23: 566–577.
Luo, J.L., S. Maeda, L.C. Hsu, et al. 2004. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6: 297–305.
Pandol, S., M. Edderkaoui, I. Gukovsky, et al. 2009. Desmo- plasia of pancreatic ductal adenocarcinoma. Clin. Gastroen- terol. Hepatol. 7: S44–S47.
Tsang, S.W., H. Zhang, Z. Lin, et al. 2015. Anti-fibrotic effect of trans-resveratrol on pancreatic stellate cells. Biomed. Phar- macother. 71: 91–97.
Lin, Z., L.C. Zheng, H.J. Zhang, et al. 2015. Anti-fibrotic effects of phenolic compounds on pancreatic stellate cells. BMC Complement. Altern. Med. 15: 259.
Qian, D., Z. Lu, Q. Xu, et al. 2017. Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis. Cancer Lett. 397: 43–51.
Pietras, K., J. Pahler, G. Bergers, et al. 2008. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5: e19.
Hirakawa, T., M. Yashiro, Y. Doi, et al. 2016. Pancreatic fibroblasts stimulate the motility of pancreatic cancer cells through IGF1/IGF1R signaling under hypoxia. PLoS One 11: e0159912.
Gonzales, A.M. & R.A. Orlando. 2008. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr. Metab. 5: 17.
Tome-Carneiro, J., M. Gonzalvez, M. Larrosa, et al. 2013. Grape resveratrol increases serum adiponectin and down- regulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 27: 37–48.
Sharma, S., K. Chopra, S.K. Kulkarni, et al. 2007. Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin. Exp. Immunol. 147: 155–163.
Tang, H.Y., A. Shih, H.J. Cao, et al. 2006. Resveratrol- induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther. 5: 2034– 2042.
Bishayee, A., A. Waghray, K.F. Barnes, et al. 2010. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm. Res. 27: 1080–1091.
Brakenhielm, E., R. Cao & Y. Cao. 2001. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 15: 1798–1800.
Mo, W., X. Xu, L. Xu, et al. 2011. Resveratrol inhibits proliferation and induces apoptosis through the hedgehog signaling pathway in pancreatic cancer cell. Pancreatology 11: 601–609.
Snyder, R.M., W. Yu, L. Jia, et al. 2008. Vitamin E analog alpha-TEA, methylseleninic acid, and transresveratrol in combination synergistically inhibit human breast cancer cell growth. Nutr. Cancer 60: 401–411.
Colin, D., A. Gimazane, G. Lizard, et al. 2009. Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells. Int. J. Cancer 124: 2780–2788.
Olive, K.P., M.A. Jacobetz, C.J. Davidson, et al. 2009. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457–1461.
Huang, H., H. Lin, X. Zhang, et al. 2012. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-kappaB-dependent pathway. Oncol. Rep. 27: 2050–2056.
Kala, R., H.N. Shah, S.L. Martin, et al. 2015. Epigenetic- based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent -H2AX and telomerase regulation in triple-negative breast cancer. BMC Cancer 15: 672.
Xu, J., D. Liu, H. Niu, et al. 2017. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial–mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer. J. Exp. Clin. Cancer Res. 36: 19.
Vinod, B.S., H.H. Nair, V. Vijayakurup, et al. 2015. Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel- mediated activation of HER-2-Akt axis. Cell Death Discov. 1: 15061.
Dun, J., X. Chen, H. Gao, et al. 2015. Resveratrol synergistically augments anti-tumor effect of 5-FU in vitro and in vivo by increasing S-phase arrest and tumor apoptosis. Exp. Biol. Med. 240: 1672–1681.
Tamburrino, A., G. Piro, C. Carbone, et al. 2013. Mecha- nisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front. Pharmacol. 4: 56.
Fernandes, M.S., F. Carneiro, C. Oliveira, et al. 2013. Col- orectal cancer and RASSF family—a special emphasis on RASSF1A. Int. J. Cancer 132: 251–258.
Zhu, W., W. Qin, K. Zhang, et al. 2012. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr. Cancer 64: 393–400.
Nguyen,A.V.;Martinez,M.;Stamos,M.J.;Moyer,M.P.;Planutis,K.;Hope,C.;Holcombe,R.F.Resultsof a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Managen. Res. 2009, 1, 25–37.
Popat, R., T. Plesner, F. Davies, et al. 2013. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br. J. Haema- tol. 160: 714–717.
Delcò, F., Tchambaz, L., Schlienger, R., Drewe, J., Krähenbühl, S. (2005). Dose adjustment in patients with liver disease. Drug Saf 28:529–545.
Chow, H.-H. S., Garland, L. L., Hsu, C.-H., Vining, D. R., Chew, W. M., Miller, J. A., et al. (2010). Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3:1168–1175.
Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., van Breemen, R. B. (2003). Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom 17:307–313.
Chan, W. K., Delucchi, A. B. (2000). Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 67:3103–3112.
Shanmugam, M.K.; Nguyen, A.H.; Kumar, A.P.; Tan, B.K.; Sethi, G. Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer. Cancer Lett. 2012, 320, 158–170.
Shanmugam, M.K.; Lee, J.H.; Chai, E.Z.; Kanchi, M.M.; Kar, S.; Arfuso, F.; Dharmarajan, A.; Kumar, A.P.; Ramar, P.S.; Looi, C.Y.; et al. Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds. Semin. Cancer Biol. 2016, 40–41, 35–47.
Prasannan, R.; Kalesh, K.A.; Shanmugam, M.K.; Nachiyappan, A.; Ramachandran, L.; Nguyen, A.H.; Kumar, A.P.; Lakshmanan, M.; Ahn, K.S.; Sethi, G. Key cell signaling pathways modulated by zerumbone: Role in the prevention and treatment of cancer. Biochem. Pharmacol. 2012, 84, 1268–1276.
A. Wahab, K. Gao, C. Jia, F. Zhang, G. Tian, G. Murtaza, J. Chen, Significance of resveratrol in clinical management of chronic diseases, Molecules 22 (2017),
J.-H. Ko, G. Sethi, J.-Y. Um, M.K. Shanmugam, F. Arfuso, A.P. Kumar, A. Bishayee, K.S. Ahn, The role of resveratrol in cancer therapy, Int. J. Mol. Sci. 18 (2017) 2589,
M. Jang, L. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W. Beecher, H.H. Fong,
N.R. Farnsworth, A.D. Kinghorn, R.G. Mehta, et al., Cancer chemopreventive activity of resveratrol, a natural product derived from grapes, Science (New York, N.Y.) 275 (1997) 218–220,
S.H. Baek, J.-H. Ko, H. Lee, J. Jung, M. Kong, J.-w. Lee, J. Lee, A. Chinnathambi, M. E. Zayed, S.A. Alharbi, et al., Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: role in apoptosis induction and radiosensitization in head and neck tumor cells, Phytomedicine 23 (2016) 566–577.
K.B. Harikumar, A.B. Kunnumakkara, G. Sethi, P. Diagaradjane, P. Anand, M. K. Pandey, J. Gelovani, S. Krishnan, S. Guha, B.B. Aggarwal, Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer, Int. J. Canc. 127 (2010) 257–268
Jang, M., L. Cai, G.O. Udeani, et al. 1997. Cancer chemo- preventive activity of resveratrol, a natural product derived from grapes. Science 275: 218–220.
Kumar, S., E. Eroglu, J.A. Stokes, 3rd, et al. 2017. Resveratrol induces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancer cells. Oncotarget 8: 20895–20908.
Vendrely, V., E. Peuchant, E. Buscail, et al. 2017. Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model. Cancer Lett. 390: 91– 102.
(thickness >3 mm) or regional lymph node metastasis. Eur J Cancer. 2004;40(3):390-402.
Low, I.C., Z.X. Chen & S. Pervaiz. 2010. Bcl-2 modulates resveratrol-induced ROS production by regulating mitochondrial respiration in tumor cells. Antioxid. Redox Signal. 13: 807–819.
Cao, L., X. Chen, X. Xiao, et al. 2016. Resveratrol inhibits hyperglycemia-driven ROS-induced invasion and migration of pancreatic cancer cells via suppression of the ERK and p38 MAPK signaling pathways. Int. J. Oncol. 49: 735–743.
Thiel, G. & O.G. Rossler. 2014. Resveratrol stimulates AP-1- regulated gene transcription. Mol. Nutr. Food Res. 58: 1402– 1413.
Kong,Y.,G.Chen,Z.Xu,etal.2016.Pterostilbeneinduces apoptosis and cell cycle arrest in diffuse large B-cell lym- phoma cells. Sci. Rep. 6: 37417.
Cote, C.D., B.A. Rasmussen, F.A. Duca, et al. 2015. Resvera- trol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat. Med. 21: 498–505.
Farrand, L., S. Byun, J.Y. Kim, et al. 2013. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modula- tion of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission. J. Biol. Chem. 288: 23740–23750.
Li, W., J. Ma, Q. Ma, et al. 2013. Resveratrol inhibits the epithelial–mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-kappaB pathway. Curr. Med. Chem. 20: 4185–4194.
Li, W., L. Cao, X. Chen, et al. 2016. Resveratrol inhibits hypoxia-driven ROS-induced invasive and migratory ability of pancreatic cancer cells via suppression of the Hedgehog signaling pathway. Oncol. Rep. 35: 1718–1726.
Jiang, Z., X. Chen, K. Chen, et al. 2016. YAP inhibition by resveratrol via activation of AMPK enhances the sensitivity of pancreatic cancer cells to gemcitabine. Nutrients 8: 546.
Thiel, G. & O.G. Rossler. 2014. Resveratrol stimulates AP-1- regulated gene transcription. Mol. Nutr. Food Res. 58: 1402– 1413.
Zhu, Y., Y. Sun, W. Guan, et al. 2016. Lycium barbarum polysaccharides enhances SIRT1 expression and decreases MMP-9 and HIF-1expressions in hypoxic pulmonary vas- cular smooth muscle cells. Xi bao yu fen zi mian yi xue za zhi 32: 906–910.
Baek, S.H., J.H. Ko, H. Lee, et al. 2016. Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: role in apoptosis induction and radiosensitization in head and neck tumor cells. Phytomedicine 23: 566–577.
Luo, J.L., S. Maeda, L.C. Hsu, et al. 2004. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6: 297–305.
Pandol, S., M. Edderkaoui, I. Gukovsky, et al. 2009. Desmo- plasia of pancreatic ductal adenocarcinoma. Clin. Gastroen- terol. Hepatol. 7: S44–S47.
Tsang, S.W., H. Zhang, Z. Lin, et al. 2015. Anti-fibrotic effect of trans-resveratrol on pancreatic stellate cells. Biomed. Phar- macother. 71: 91–97.
Lin, Z., L.C. Zheng, H.J. Zhang, et al. 2015. Anti-fibrotic effects of phenolic compounds on pancreatic stellate cells. BMC Complement. Altern. Med. 15: 259.
Qian, D., Z. Lu, Q. Xu, et al. 2017. Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis. Cancer Lett. 397: 43–51.
Pietras, K., J. Pahler, G. Bergers, et al. 2008. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5: e19.
Hirakawa, T., M. Yashiro, Y. Doi, et al. 2016. Pancreatic fibroblasts stimulate the motility of pancreatic cancer cells through IGF1/IGF1R signaling under hypoxia. PLoS One 11: e0159912.
Gonzales, A.M. & R.A. Orlando. 2008. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr. Metab. 5: 17.
Tome-Carneiro, J., M. Gonzalvez, M. Larrosa, et al. 2013. Grape resveratrol increases serum adiponectin and down- regulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 27: 37–48.
Sharma, S., K. Chopra, S.K. Kulkarni, et al. 2007. Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin. Exp. Immunol. 147: 155–163.
Tang, H.Y., A. Shih, H.J. Cao, et al. 2006. Resveratrol- induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther. 5: 2034– 2042.
Bishayee, A., A. Waghray, K.F. Barnes, et al. 2010. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm. Res. 27: 1080–1091.
Brakenhielm, E., R. Cao & Y. Cao. 2001. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 15: 1798–1800.
Mo, W., X. Xu, L. Xu, et al. 2011. Resveratrol inhibits proliferation and induces apoptosis through the hedgehog signaling pathway in pancreatic cancer cell. Pancreatology 11: 601–609.
Snyder, R.M., W. Yu, L. Jia, et al. 2008. Vitamin E analog alpha-TEA, methylseleninic acid, and transresveratrol in combination synergistically inhibit human breast cancer cell growth. Nutr. Cancer 60: 401–411.
Colin, D., A. Gimazane, G. Lizard, et al. 2009. Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells. Int. J. Cancer 124: 2780–2788.
Olive, K.P., M.A. Jacobetz, C.J. Davidson, et al. 2009. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457–1461.
Huang, H., H. Lin, X. Zhang, et al. 2012. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-kappaB-dependent pathway. Oncol. Rep. 27: 2050–2056.
Kala, R., H.N. Shah, S.L. Martin, et al. 2015. Epigenetic- based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent -H2AX and telomerase regulation in triple-negative breast cancer. BMC Cancer 15: 672.
Xu, J., D. Liu, H. Niu, et al. 2017. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial–mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer. J. Exp. Clin. Cancer Res. 36: 19.
Vinod, B.S., H.H. Nair, V. Vijayakurup, et al. 2015. Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel- mediated activation of HER-2-Akt axis. Cell Death Discov. 1: 15061.
Dun, J., X. Chen, H. Gao, et al. 2015. Resveratrol synergistically augments anti-tumor effect of 5-FU in vitro and in vivo by increasing S-phase arrest and tumor apoptosis. Exp. Biol. Med. 240: 1672–1681.
Tamburrino, A., G. Piro, C. Carbone, et al. 2013. Mecha- nisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front. Pharmacol. 4: 56.
Fernandes, M.S., F. Carneiro, C. Oliveira, et al. 2013. Col- orectal cancer and RASSF family—a special emphasis on RASSF1A. Int. J. Cancer 132: 251–258.
Zhu, W., W. Qin, K. Zhang, et al. 2012. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr. Cancer 64: 393–400.
Nguyen,A.V.;Martinez,M.;Stamos,M.J.;Moyer,M.P.;Planutis,K.;Hope,C.;Holcombe,R.F.Resultsof a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Managen. Res. 2009, 1, 25–37.
Popat, R., T. Plesner, F. Davies, et al. 2013. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br. J. Haema- tol. 160: 714–717.
Delcò, F., Tchambaz, L., Schlienger, R., Drewe, J., Krähenbühl, S. (2005). Dose adjustment in patients with liver disease. Drug Saf 28:529–545.
Chow, H.-H. S., Garland, L. L., Hsu, C.-H., Vining, D. R., Chew, W. M., Miller, J. A., et al. (2010). Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3:1168–1175.
Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., van Breemen, R. B. (2003). Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom 17:307–313.
Chan, W. K., Delucchi, A. B. (2000). Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 67:3103–3112.
Sayfalar
323-330
Yayınlanan
11 Mart 2024
Telif Hakkı (c) 2024 Akademisyen Yayınevi Kitap Portalı
Lisans
LisansNasıl Atıf Yapılır
1.
Bilen İ. Resveratrol. Içinde: Sakin A, editör. Kanser Hastalarının Başvurduğu Geleneksel ve Tamamlayıcı Tedaviler - Tıbbi Onkolog Gözü ile Bakış ve Onkolojik İlaçlarla Etkileşim [Internet]. Türkiye: Akademisyen Yayınevi Kitap DOI Portalı; 2024 [a.yer 13 Temmuz 2026]. ss. 323-30. Erişim adresi: https://www.omp35.books.akademisyen.net/index.php/akya/catalog/book/2380/chapter/13935
